Welcome
Pharmaceutical & Life Sciences News

Gilead, BMS, J&J Hit With Second Truvada Antitrust Class Action

Jan. 15, 2020, 9:04 PM

Gilead Sciences Inc., Bristol-Myers Squibb Co., Johnson & Johnson, and Japan Tobacco Inc. were sued in Miami federal court Wednesday over their alleged conspiracy to corner the market for HIV prevention therapies like Gilead’s $11-billion-a-year drug Truvada.

“The scheme enabled Gilead and its co-conspirators to unlawfully extend patent protection for their drugs, impair entry by generic competitors, and charge exorbitant, supra-competitive prices for the drugs that people living with HIV need to survive,” the lawsuit says.

Gilead called the claims meritless in a statement, saying the suit “distorts and misstates Gilead’s history and its collaborations with these...

To read the full article log in. To learn more about a subscription click here.